Background:Adverse drug events are more common in elderly people, prompting the Japan Geriatrics Society to update its "Guidelines for Safe Pharmacotherapy in the Elderly" in 2025. In this revision, glucagon-like peptide-1 receptor agonist (GLP-1RA) and glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA) were newly added to the list of drugs requiring special caution. This study aimed to descriptively investigate real-world prescribing patterns of GLP-1RAs and their concomitant use with other glucose-lowering drugs (GLDs) requiring special caution among elderly people with type 2 diabetes (T2D). Methods:This single-center, retrospective, cross-sectional, exploratory descriptive study included outpatients aged ≥ 65 years with T2D who received antihyperglycemic therapy between September and December 2025. Clinical characteristics, laboratory data, and prescription records were extracted from electronic medical records. Descriptive analyses were conducted stratified by GLP-1RA use (users vs. non-users) and by age categories (65 to < 75 years and ≥ 75 years). Results:Among 214 eligible people with T2D, 50 (23.4%) were prescribed GLP-1RAs. Among GLP-1RA users, 63.0% were classified as having obesity, and the mean number of concomitant GLDs was 3.2 ± 0.8. GLP-1RAs were often prescribed concomitantly with other GLDs requiring special caution in elderly people, including metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), sulfonylureas, and insulin. In age-stratified analyses, oral semaglutide and dulaglutide were the most prescribed GLP-1RAs among people aged ≥ 75 years. Conclusions:GLP-1RAs were prescribed to approximately one quarter of elderly people with T2D and were most commonly used in people with obesity and more complex glucose-lowering regimens. Their frequent concomitant use with other drugs requiring special caution underscores the complexity of pharmacological management in elderly people.

Purpose: The cardio-ankle vascular index (CAVI) is a blood pressure-independent indicator of arterial stiffness. Although CAVI is associated with metabolic risk factors, longitudinal evidence clarifying their relative impact remains limited. This study aimed to examine longitudinal associations between metabolic abnormalities and CAVI in a Japanese health check-up population, focusing on MetS components and waist circumference (WC) status. Patients and Methods: A total of 13,724 adults (7060 men and 6664 women) who underwent annual health check-ups at the International University of Health and Welfare Narita Hospital between 2020 and 2024 were included. Linear mixed-effects models were used to evaluate longitudinal changes in CAVI according to MetS components (blood pressure, glucose, lipids, and WC). Secondary analyses examined CAVI changes by MetS status, WC strata (WC (+)/WC (-)), metabolic risk count (0-3) and sex. Results: Older age and male sex were independently associated with higher CAVI. Blood pressure and glucose abnormalities showed the strongest associations with elevated CAVI, whereas lipid risk had a modest effect and WC was inversely associated with CAVI. CAVI increased annually overall, but increased more slowly among participants with blood pressure risk. Time interactions for glucose, lipid and WC risk were not significant. MetS was associated with higher baseline CAVI, but longitudinal time interactions did not differ significantly by MetS status. In WC-stratified analyses, baseline CAVI increased stepwise with accumulation of metabolic risk factors in both WC (+) and WC (-) groups, including a substantial WC (-)-subgroup-particularly women-with multiple metabolic risks and elevated CAVI. Conclusion: Longitudinal follow-up revealed modest CAVI progression with attenuated slopes among participants with high-baseline CAVI, indicating that baseline CAVI captures cumulative vascular injury rather than accelerated short-term change. CAVI may complement WC-centered screening by identifying non-obese individuals-especially women-with elevated longitudinal vascular risk.

Advanced ovarian cancer carries a poor prognosis despite standard surgery and chemotherapy. Although poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib and niraparib, have recently become standard maintenance therapy, they can cause hematologic and non-hematologic toxicities, and data on their safety in older Japanese patients are limited. We aimed to evaluate the incidence of clinically significant severe adverse events (SAEs), treatment interruptions, and discontinuation of PARP inhibitor maintenance therapy according to age in Japanese patients with ovarian cancer. This retrospective cohort study used data from the Japanese Diagnosis Procedure Combination database. Patients diagnosed with ovarian cancer who received treatment with PARP inhibitors approved in Japan (olaparib, olaparib plus bevacizumab, or niraparib) after surgery and chemotherapy were included. Clinically significant SAEs were identified using diagnostic and billing codes rather than laboratory-confirmed Common Terminology Criteria for Adverse Events (CTCAE) grading. Outcomes were assessed across two age groups (< 65 vs. ≥ 65 years) using inverse probability weighting to account for baseline differences. After adjustment, the baseline characteristics were balanced among the 1083 patients included in this study (olaparib, 315; olaparib plus bevacizumab, 343; niraparib, 425). In the olaparib group, patients aged ≥ 65 years showed a higher incidence of clinically significant neutropenia compared with those aged < 65 years (incidence rate ratio 7.47; 95

Ventilator-associated pneumonia (VAP) has a considerable impact on both clinical outcomes and healthcare costs. This study compared 40 patients having VAP with 40 matched controls from a Japanese ICU dataset. Patients with VAP experienced significantly longer ICU and hospital stays, fewer ventilator-free days, and a higher incidence of tracheostomies. VAP cases also required more broad-spectrum antimicrobials, leading to an additional cost of approximately USD 24,410 per case. These results highlight the importance of implementing effective infection control strategies to mitigate VAP's clinical and economic consequences.

While both intermittent renal replacement therapy (IRRT) and continuous renal replacement therapy (CRRT) are used to treat sepsis-associated acute kidney injury (S-AKI), their comparative effectiveness remains unclear. We compared the outcomes between these modalities in patients with S-AKI. Data from the Japanese Intensive Care Patient Database (JIPAD) was used for this multi-center retrospective cohort study. Adult patients with S-AKI who received either IRRT or CRRT between 2015 and 2021 were included. The primary outcome was in-hospital mortality. We compared IRRT and CRRT using one-to-three propensity score matching analysis. A subgroup analysis was performed in patients with septic shock. Of the 756 patients analyzed, 79 received IRRT, and 677 received CRRT. After propensity score matching, baseline characteristics were well-balanced between groups. In-hospital mortality showed no significant difference between IRRT and CRRT (48.6

BACKGROUND:Non-small-cell-lung cancer (NSCLC) medication use and guideline adherence remain unclear. We investigated treatment patterns and adherence among Japanese patients with NSCLC. RESEARCH DESIGN AND METHODS:We analyzed treatment patterns and guideline adherence by age and histology in ≥ 20-year-olds with stage IV NSCLC treated between 2016-2018 using diagnostic procedure combination data. Logistic regression analysis evaluated the impact of various factors on guideline adherence. RESULTS:We included 9,722 patients. In < 75-year-olds with nonsquamous NSCLC, first-to third-line treatments comprised 31.8% platinum combination therapy, 26.3% immune checkpoint inhibitors, and 62.5% cytotoxic chemotherapy. In ≥ 75-year-olds, first-line and second-line molecular targeted therapies represented 46.6% and 35.6%, whereas third-line cytotoxic chemotherapy represented 42.3%. In squamous NSCLC, first-line platinum combination therapy was predominant (69.7% and 47.7% for < 75-and ≥75-year-olds). The most common second-line and third-line therapies were immune checkpoint inhibitors (48.6% and 50.8% for < 75-and ≥75-year-olds) and cytotoxic chemotherapy (62.5% and 55.2% for < 75-and ≥75-year-olds), respectively. The highest guideline adherence (90%) was in < 75-year-olds with squamous NSCLC. Age, histology, activities of daily living, and cumulative hospitalizations over the past 18 months influenced treatment adherence. CONCLUSION:New NSCLC drug introduction increased regardless of age, suggesting prognosis improvement. More efficient drug application and broader guideline dissemination are required.

AbstractAimEmergency resuscitative thoracotomy is a potentially lifesaving procedure for patients with cardiac pulmonary arrest and profound circulatory failure resulting from a severe injury. However, survival rate post‐emergency resuscitative thoracotomy shows considerable variation, with many studies constrained by limited sample sizes and ambiguous criteria for inclusion. Herein, we assessed the outcomes of emergency resuscitative thoracotomy and identified predictors of futility using Japan Trauma Data Bank data.MethodsData of patients aged ≥18 years between 2004 and 2019 were analyzed. The primary outcome measure was survival at discharge. Descriptive statistics were used to compare the survivor and nonsurvivor groups. A multivariable logistic regression analysis was conducted to identify predictors of survival in patients undergoing emergency resuscitative thoracotomy while adjusting for confounding factors.ResultsAmong patients who underwent emergency resuscitative thoracotomy, 684/5062 (13.5%) survived. Age <65 years (adjusted odds ratio, 1.351; 95% confidence interval, 1.130–1.615; p < 0.001), absence of cardiac pulmonary arrest on emergency department arrival (adjusted odds ratio, 1.694; 95% confidence interval, 1.280–2.243; p < 0.01), Injury Severity Score <16 (adjusted odds ratio, 2.195; 95% confidence interval, 1.611–2.992; p < 0.01), and penetrating injury (adjusted odds ratio, 1.834; 95% confidence interval, 1.384–2.431; p < 0.01) were identified as factors associated with survival at discharge.ConclusionThe survival rate for emergency resuscitative thoracotomy in Japan stands at approximately 13.5%. Factors contributing to survival include younger age, absence of cardiopulmonary arrest at emergency department arrival, lack of severe trauma, and sustaining penetrating injuries.

Objectives: It is unclear whether patients with acute pulmonary thromboembolism (PE) with and without residual deep vein thrombosis (DVT) have different prognoses, and there is debate over whether inferior vena cava filters (IVCFs) should be used in conjunction with oral anticoagulants in patients with venous thromboembolism (VTE). Materials and Methods: The J'xactly involved 1,016 patients and was a multicenter, prospective, observational research. In this subanalysis, 419 patients with PE with or without residual DVT who received rivaroxaban with or without IVCFs between February 2016 and April 2018 in Japan were examined. Results: Of 419 patients with PE, 320 had residual DVT. There was no difference between the groups with and without DVT in terms of the percentage of patients who experienced symptomatic PE recurrence (2.8% [9/320] vs. 3.0% [3/99]) or who died from VTE-related complications (0.9% [3/320] vs. 1.0% [1/99]). The percentages of patients with symptomatic PE recurrence were 0% and 3.2%, and the percentages of patients who died from VTE-related causes were 0% and 1.1%, respectively, in the groups with (n=39) and without (n=281) IVCF, albeit not being statistically different. Conclusion: Patients with PE with and without residual DVT did not have a different incidence of symptomatic PE recurrence. These results require additional study to be confirmed.

Introduction: Increased long-term blood pressure variability (BPV), defined as monthly to yearly BPV, has been reported a risk factor of cardiovascular events independent of mean BP level. However, the relationship between long-term BPV and decrease in GFR remains unknown. In this study, we examined the association of Long-Term BPV and decrease in GFR. Methods: We included 214,443 type 2 diabetes mellitus patients with hypertension, registered in the Japan Diabetes Data Management Study Group, whose BP and HbA1c were simultaneously measured at least 4 times per year for 5 years from 2014-2018. BPV was defined as the 5-year coefficient of variation (CV), and the relationship between BPV and eGFR was examined. We also examined the relationship between BPV and the following background factors: (1) age (2) duration of diabetes (3) HbA1c (4) antihypertensive medications. The Ca-antagonist group was patients who took only Ca-antagonists during the 5-year period, and the ARB group was patients who took only ARBs. This study was a retrospective analysis. Data analyses were performed using the SPSS 28.0 software. Results: The group with greater 5-year BPV had lower eGFR than the group with smaller BPV, independent of mean BP (P<0.001). Regarding BPV and patient background, (1) BPV tended to increase with increasing age, and was significantly greater in patients over 50 years of age compared to those in their 30s (P<0.001). (2) The longer diabetic duration, the greater the BPV (P<0.001). Especially in patients more than 20 years’ diabetic duration, BPV was significantly larger than that of less than 5 years (P<0.001). (3) There was no association between HbA1c and BPV. (4) BPV was significantly lower in the Ca antagonist group compared with the ARB group over 5 years (0.069 vs. 0.078 P<0.001). Conclusion: Increased long-term BPV was observed older age and long duration of diabetes, but was not related to HbA1c. Interestingly, Patients with greater BPV had lower eGFR at 5 years. Disclosure M.Sakamoto: None. M.Yuki: None. K.Miyashita: None. T.Yamazaki: None.

Background An established treatment strategy for asymptomatic pulmonary embolism (PE) or deep vein thrombosis (DVT) remains uncertain in Japan; therefore, in this study, we clarify the characteristics and outcomes of symptomatic compared to asymptomatic patients with PE or DVT. Methods This prospective, multicenter sub-analysis of the J’xactly study in Japan included 1,016 patients (mean age, 68; 41% male) with venous thromboembolism (VTE) treated with rivaroxaban. Results Asymptomatic PE patients (47% of PE patients) were more likely to have active cancer and asymptomatic proximal DVT at lower severity than symptomatic PE patients, despite no differences in age, sex, or the proportion receiving intensive 30 mg/day-rivaroxaban. Patients with asymptomatic DVT (34% of DVT patients) were older, had higher rates of female sex, active cancer, and distal DVT, and received shorter, less intense rivaroxaban treatment. Incidences did not differ between asymptomatic and symptomatic PE patients for recurrent symptomatic VTE (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.22–1.62; P = 0.31) or major bleeding (HR, 0.68; 95% CI, 0.20–2.33; P = 0.58), nor between asymptomatic and symptomatic DVT patients for recurrent symptomatic VTE (HR, 0.56; 95% CI, 0.23–1.40; P = 0.21) and major bleeding (HR, 1.47; 95% CI, 0.54–3.97; P = 0.45). Conclusions The real-world composite adverse event rate for treatment with rivaroxaban, as physician-adjusted for dose and duration, was similar for asymptomatic and symptomatic patients regardless of the presence of PE or DVT, suggesting a favorable safety profile for potential rivaroxaban treatment for asymptomatic VTE.

This study aimed to investigate the association between daily sleep duration of <7 hours and lower bone mineral density (BMD) using data from annual health check-ups conducted in Japan between 2020 and 2022. Multivariate regression models were used, where BMD was the objective variable and daily sleep duration (<5 hours, 5 to <7 hours, 7 to <9 hours [reference], ≥9 hours) was the exposure variable adjusted for age, body mass index, physical activity, smoking status, and alcohol intake for men and women and further adjusted for menopausal status for women. The association between insomnia and BMD was also investigated. BMD was determined using calcaneal quantitative ultrasound and expressed as a percentage of the young adult mean (%YAM). In total, 896 men and 821 women were included. Median age was 54 years (interquartile range [IQR]: 46 to 64) for men and 55 years (IQR: 46 to 64) for women). Median BMD for men and women was 79%YAM (IQR: 71 to 89) and 75%YAM (IQR: 68 to 84), respectively. Approximately 80% of men and women slept <7 hours daily. Multivariate regression showed no association between sleep duration and BMD in men. However, women who slept 5 to <7 hours daily had significantly higher BMD by 3.9% compared with those who slept 7 to<9 hours (p = 0.004). No association between insomnia and BMD was found. Overall, a daily sleep duration of <7 hours was not independently associated with lower BMD compared to those who slept 7 to <9 hours in men and women. However, as there is evidence of both shorter and longer sleep durations being associated with an increased risk of adverse events, including cardiovascular events, our result needs to be interpreted with caution. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

BackgroundD-dimer is a biomarker of fibrin production and degradation, and changes in D-dimer concentration suggest fibrin clot formation, which is associated with thromboembolism and hypercoagulable states. Thus, an elevated D-dimer concentration could be a useful prognostic predictor for patients with venous thromboembolism (VTE).Methods and resultsIn this subanalysis of the J’xactly study, a prospective multicenter study conducted in Japan, we examined the clinical outcomes of 949 patients with VTE stratified by baseline D-dimer concentration. The median D-dimer concentration was 7.6 μg/ml (low D-dimer group: <7.6 μg/ml [n = 473, 49.8%]; high D-dimer group: ≥7.6 μg/ml [n = 476, 50.2%]). The mean age of the patients was 68 years, and 386 patients (40.7%) were male. Compared with the low D-dimer group, the high D-dimer group had more frequent pulmonary embolism with or without deep vein thrombosis (DVT), proximal DVT, atrial fibrillation, or diabetes mellitus, and underwent intensive treatment with 30 mg/day rivaroxaban. The incidence of composite clinically relevant events (recurrence or exacerbation of symptomatic VTE, acute coronary syndrome [ACS], ischemic stroke, death from any cause, or major bleeding) was higher in the high D-dimer group than in the low D-dimer group (11.1% vs. 7.5% per patient-year; hazard ratio, 1.46; 95% confidence interval, 1.05–2.04; p = 0.025). There was no significant difference between the high and low D-dimer groups in the incidence of VTE (2.8% vs. 2.5% per patient-year, respectively; p = 0.788), ACS (0.4% per patient-year vs. not observed, respectively; p = 0.078), or major bleeding (4.0% vs. 2.1% per patient-year, respectively; p = 0.087), but there was a significant difference in the incidence of ischemic stroke (1.0% per patient-year vs. not observed, respectively; p = 0.004).ConclusionElevated D-dimer concentration may be an important prognostic predictor in Japanese patients with VTE.Clinical Trial Registration: UMIN CTR, UMIN000025072 (https://www.umin.ac.jp/ctr/index.htm).

Remifentanil, characterized by its ultra-short action duration and nonorgan-dependent metabolism, is applied in postcardiac surgery settings worldwide. While previous studies have compared its efficacy with that of other opioids, it has never been compared to a single specific opioid. Here, we evaluated whether remifentanil shortens mechanical ventilation (MV) times in patients after cardiac surgery. We identified randomized controlled trials that compared various opioids in adults (>= 18 years) admitted to the intensive care unit after cardiac surgery. The primary outcome was the duration of MV, expressed as the mean difference (MD) in minutes, with a 95% confidence interval (CI). A 60-min reduction was considered significant based on prior research. Data were sourced from MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, the World Health Organization International Clinical Trials Platforms Search Portal, and ClinicalTrials.gov, and a frequentist network meta-analysis was conducted. The eight identified studies indicate no differences in the duration of MV between remifentanil and fentanyl (MD 0.09 min; 95%CI -36.89-37.08), morphine (MD -19 min; 95%CI -55.86-16.21), or sufentanil (MD -2.44 min; 95%CI 67.52-62.55). Our study revealed that remifentanil did not reduce MV times in patients after cardiac surgery. The study protocol was registered with the Open Science Forum (https://osf.io/) (DOI

Aim: There is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. The aim of this study was to evaluate the relationships of serum TG levels and sdLDL-C levels as residual risks for cardiovascular events in patients with CAD and type 2 DM who were being treated with statins. Methods: The subjects were divided into four groups based on TG levels and sdLDL-C levels: sdLDL-C of ＜40.0 mg/dL and TG of ＜150 mg/dL, sdLDL-C of ≥ 40.0 mg/dL and TG of ＜150 mg/dL, sdLDL-C of ＜40.0 mg/dL and TG of ≥ 150 mg/dL, and sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL. During a median follow-up period of 1419 days, cardiovascular events occurred in 34 patients. Results: The incidences of cardiovascular events were significantly higher in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ＜150 mg/dL and in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL, but not in patients with sdLDL-C of ＜40.0 mg/dL and TG of ≥ 150 mg/dL, than in patients with sdLDL-C of ＜40.0 mg/dL and TG of ＜150 mg/dL. Conclusions: Under the condition of treatment with statins, patients with CAD and type 2 DM who had sdLDL-C levels of ≥ 40.0 mg/dL had a high risk for cardiovascular events even though serum TG levels were controlled at ＜150 mg/dL.

Introduction: The seasonal fluctuation of estimated glomerular filtration rate (GFR) in type2 diabetes mellitus (T2DM) patients remains unknown. The present study is first to examine seasonal fluctuation of eGFR and its relationship to the progression of diabetic nephropathy (DN). Methods: This retrospective study initially analyzed data on 21,307 T2DM patients with hypertension (HT). Seasonal fluctuation of eGFR were evaluated using the intrapersonal coefficient of variation (CV) of 20 or more serial measurements of body weight, Blood pressure and HbA1c during a 5-year period from 2014-2018. The primary objective was to determine if there is seasonal fluctuation of eGFR or not. Secondary objective is to examine the relationship between progression of DN and seasonal fluctuation of eGFR. DN was assessed by eGFR and urinary albumin excretion (UAE) changes. Results: The figure shows the changes of eGFR monthly averages. eGFR is significantly lower in summer each year (vs winter, P<0.001). Classified into two groups based on median CV of eGFR, eGFR decrease was obvious in the group with large CV of eGFR (vs group with small CV, P<0.001). In addition, UAE increase was also obvious in the group with large CV of eGFR (vs group with small CV, P<0.001). Conclusion: This study suggests that eGFR is fluctuated by season in T2DM patients with HT. The seasonal fluctuation of eGFR was associated with the progression of DN. Disclosure M.Yuki: None. T.Yamazaki: None. K.Miyashita: None. M.Sakamoto: None.

Type 2 diabetes mellitus (T2DM) is a major cause of microvascular dysfunction. However, its effect on blood flow patterns during ischemic demand has not been adequately elucidated. In this study, we investigated the hypothesis that microvascular dysfunction in patients with T2DM manifests as brachial reactive hyperemia (BRH), defined as the ratio of peak blood flow velocities in a brachial artery before and after forearm cuff occlusion. The study enrolled 943 subjects (men, n = 152 [T2DM] and n = 371 [non-T2DM]; women, n = 107 [T2DM] and n = 313 [non-T2DM], respectively) with no history of cardiovascular disease. Semiautomatic measurements were obtained three times at 1.5-year intervals to confirm the reproducibility of factors involved in BRH for each sex. An age-adjusted mixed model demonstrated attenuated BRH in the presence of T2DM in both men (p = 0.022) and women (p = 0.031) throughout the study period. Post hoc analysis showed that the estimated BRH was significantly attenuated in patients with T2DM regardless of sex, except at baseline in women. In multivariate regression analysis, T2DM was a negative predictor of BRH at every measurement in men. For women, BRH was more strongly associated with alcohol consumption. Repeated measurements analysis revealed that T2DM was associated with attenuated postocclusion reactive hyperemia.

Background: Data on the effectiveness and safety of rivaroxaban for the treatment of patients with venous throm-boembolism (VTE) and active cancer are limited in the Japanese real-world setting. Methods: In this subanalysis of the J'xactly study, which was a multicenter, prospective, observational study, we evaluated the effectiveness and safety of rivaroxaban in patients with acute VTE and active cancer (n = 193) versus those without active cancer (n = 823).Results: Compared with patients without active cancer, those with active cancer demonstrated a significantly differ-ent age distribution, with fewer aged <65 and >= 75 years; a lower proportion of women; a lower mean body mass index; and a lower proportion of physical inactivity, injury, thrombophilia, and heart failure. There was no difference in the initial dose distribution of rivaroxaban between patients with and without active cancer. The incidences of re-currence or aggravation of symptomatic VTE and major bleeding were not significantly different [VTE: 1.44 % vs. 2.80 % per patient-year, hazard ratio (HR) 0.50, 95 % confidence interval (CI) 0.18-1.39, p = 0.172; major bleeding: 4.49 % vs. 2.55 % per patient-year, HR 1.80, 95 % CI 0.82-3.95, p = 0.137]. Approximately 10 % of patients with active cancer died at 6 months, with a significantly higher cumulative all-cause mortality rate than those without active cancer (23.29 % vs. 2.03 % per patient-year, HR 11.31, 95 % CI 7.30-17.53, p < 0.001).Conclusions: In patients with VTE and active cancer, rivaroxaban showed acceptable effectiveness, although clinically significant bleeding remains a concern.Clinical trial registration: UMIN Clinical Trials Registry number, UMIN000025072.(c) 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

We characterized 118 Mycoplasma pneumoniae strains isolated from three areas of Japan (Saitama, Kanagawa, and Osaka) during the period of 2019 and 2020. Genotyping of the p1 gene in these strains revealed that 29 of them were type 1 lineage (29/118, 24.6%), while 89 were type 2 lineage (89/118, 75.4%), thereby indicating that type 2 lineage was dominant in this period. The most prevalent variant of type 2 lineage was type 2c (57/89, 64%), while the second-most was type 2j, a novel variant identified in this study (30/89, 33.7%). Type 2j p1 is similar to type 2 g p1, but cannot be distinguished from reference type 2 (classical type 2) using the standard polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP) with HaeIII digestion. Thus, we used MboI digestion in the PCR-RFLP analysis and re-examined the data from previous genotyping studies as well. This revealed that most strains reported as classical type 2 after 2010 in our studies were actually type 2j. The revised genotyping data showed that the type 2c and 2j strains have been spreading in recent years and were the most prevalent variants in Japan during the time-period of 2019 and 2020. We also analyzed the macrolide-resistance (MR) mutations in the 118 strains. MR mutations in the 23S rRNA gene were detected in 29 of these strains (29/118, 24.6%). The MR rate of type 1 lineage (14/29, 48.3%) was still higher than that of type 2 lineage (15/89, 16.9%); however, the MR rate of type 1 lineage was lower than that found in previous reports published in the 2010s, while that of type 2 lineage strains was slightly higher. Thus, there is a need for continuous surveillance of the p1 genotype and MR rate of M. pneumoniae clinical strains, to better understand the epidemiology and variant evolution of this pathogen, although M. pneumoniae pneumonia cases have decreased significantly since the COVID-19 pandemic.